ABT vs KMB: How Abbott Laboratories and Kimberly-Clark Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: KMB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABT and KMB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABT and KMB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Medical Devices, the largest segment at roughly $21.4 billion in 2025 revenue, includes the FreeStyle Libre family of continuous glucose monitors, structural heart products (Navitor, TriClip), electrophysiology systems (AVEIR leadless pacemaker), vascular devices, and heart-failure technologies. Diagnostics contributes roughly $8.9 billion, Nutrition roughly $8.5 billion (anchored by Similac infant formula and Ensure adult nutrition), and Established Pharmaceuticals roughly $5.5 billion in branded generics sold primarily in emerging markets.

Full ABT guide

Kimberly-Clark is a consumer staples company that makes and sells personal care and tissue products under household brand names. Its portfolio includes Huggies diapers, Pull-Ups training pants, Kotex feminine care, Depend and Poise adult incontinence products, Kleenex tissues, Cottonelle and Scott bath tissue, and Viva paper towels. The company organizes around three segments: Personal Care (its largest and most profitable), Consumer Tissue, and a professional/away-from-home business serving offices, restaurants, and institutions (sold under the Kimberly-Clark Professional banner). Roughly half of revenue comes from outside North America, with meaningful exposure to developing and emerging markets where category penetration is still rising. Kimberly-Clark makes money by selling repeat-purchase, non-discretionary household essentials at scale, leaning on brand strength, retail distribution, and manufacturing efficiency. The business is a classic defensive staple: steady demand, modest organic growth, and a long dividend history. Headquartered in Irving, Texas, it has been a Dividend Aristocrat for decades.

Full KMB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABT drivers: FreeStyle Libre: A Platform, Not Just a Product; Cardiovascular and Electrophysiology Momentum.
• KMB drivers: Defensive, repeat-purchase demand; Emerging-market category growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. For KMB, kimberly-Clark sells largely commoditized products where private-label store brands compete aggressively on price, capping pricing power and pressuring volumes when consumers trade down.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABT if you believe its drivers more; KMB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABT and KMB guides.

ABT. ABT's trailing GAAP P/E of roughly 26x sits below its own 3-year, 5-year, and 10-year historical averages, and is modestly above the Medical Devices and Instruments industry median of roughly 25x, suggesting the market has re-rated the stock from COVID-era growth-premium levels while still assigning a quality multiple. Revenue growth has remained consistently positive in the 5-7% range even as GAAP EPS was pressured in FY2025 by a year-over-year comparison that included elevated one-time items. The FY2026 adjusted EPS guidance of $5.38-$5.58 implies a forward adjusted P/E in the high-teens to low-twenties range at recent share prices, which analysts broadly describe as modestly discounted relative to fundamental fair value estimates.

KMB. Kimberly-Clark trades at a defensive-staples multiple, lower than faster-growing consumer names but supported by a high, durable dividend yield. The valuation reflects slow organic growth offset by predictable cash flow and decades of dividend increases. It tends to be valued like a bond proxy, with the multiple sensitive to interest rates and the dividend yield as the primary anchor for income investors.

Headline figures (approximate, 2026-06-27 (TTM through Q1 2026; share price data as of June 26, 2026)): ABT shows revenue (ttm) ~$45.1 billion, revenue (fy 2025) ~$44.3 billion (+5.7% YoY), net income (fy 2025) ~$6.5 billion, net profit margin (fy 2025) ~14.7%; KMB shows revenue (ttm) ~$20 billion, operating margin ~16%, net income (ttm) ~$2.5 billion, p/e (ttm) ~18x.

ABT and KMB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABT and KMB exposure against your real portfolio. It is not an investment adviser.